This is an aggregated industry headline. Read the full story at PharmaVoice →
Beyond weight loss: Lilly aims for leadership in brain science
Lilly's neuroscience chief discusses the large pharma's aims in brain science, and how diagnostics and dosing are driving its next advancements in Alzheimer's.
By PharmaVoice
· Jul 21, 2026
· via PharmaVoice
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlinePharmaVoice
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Amgen has agreed to a $74 million settlement with investors to resolve a lawsuit that alleged the company hid …
The WeekFierceBiotech ↗
A rare disease startup with a mission to repurpose proven drugs has licensed a Chinese formulation of a well-k…
The WeekBriefing
Novo Nordisk filed suit against Eli Lilly over GLP‑1 drugs as Anthropic deepened its rare‑disease biotech work…